Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19969447 | 0.91 | RXFP1 (0.62) | RXFP1KMT2AMAOBMAOACYP2C19 | |
| SCHEMBL15071609 | 0.90 | CYP1A2 (0.56) | RXFP1KMT2AMEN1MAOBMAOA | |
| SCHEMBL19969448 | 0.88 | RXFP1 (0.59) | RXFP1KMT2AMAOBMAOACYP2C19 | |
| SCHEMBL19969451 | 0.86 | RXFP1 (0.57) | RXFP1KMT2AMAOBMAOACYP2C19 | |
| SCHEMBL8667816 | 0.85 | TSHR (0.51) | RXFP1KMT2AMEN1CYP2C19TSHR | |
| SCHEMBL7553023 | 0.85 | TSHR (0.51) | RXFP1KMT2AMEN1CYP2C19TSHR | |
| SCHEMBL18989820 | 0.85 | RXFP1 (0.61) | RXFP1KMT2AMAOBMAOACYP2C19 | |
| SCHEMBL11826620 | 0.85 | RXFP1 (0.56) | RXFP1KMT2AMAOBMAOACYP2C19 | |
| SCHEMBL10825997 | 0.82 | RXFP1 (0.54) | RXFP1KMT2AMEN1MAOBMAOA | |
| SCHEMBL7149684 | 0.82 | RXFP1 (0.47) | RXFP1KMT2AMEN1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | RXFP1 923/4885KMT2A 1996/4885MEN1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.